2.37
price down icon0.42%   -0.010
after-market Dopo l'orario di chiusura: 2.37
loading

Annovis Bio Inc Borsa (ANVS) Ultime notizie

pulisher
Aug 19, 2025

Annovis Bio Reports Q2 2025 Progress and Financials - TipRanks

Aug 19, 2025
pulisher
Aug 18, 2025

Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Michelle Chen named CEO of gene therapy play Form Bio - BioCentury

Aug 18, 2025
pulisher
Aug 18, 2025

Quant Strategy Flags Annovis Bio Inc. for Entry2025 Earnings Impact & Technical Confirmation Alerts - newsyoung.net

Aug 18, 2025
pulisher
Aug 18, 2025

Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

What makes Annovis Bio Inc. stock price move sharplyGap Up & Safe Capital Investment Plans - thegnnews.com

Aug 18, 2025
pulisher
Aug 15, 2025

Annovis Bio appoints CEO as acting CFO following executive resignation By Investing.com - Investing.com India

Aug 15, 2025
pulisher
Aug 15, 2025

Annovis Bio appoints CEO as acting CFO following executive resignation - Investing.com

Aug 15, 2025
pulisher
Aug 15, 2025

Annovis Bio Inc. Rebound Backed by Sentiment ShiftJuly 2025 Catalysts & Reliable Intraday Trade Plans - beatles.ru

Aug 15, 2025
pulisher
Aug 14, 2025

Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Annovis Bio Q2 Earnings: EPS Loss Narrows, No Revenue Reported, Cash and Cash Equivalents Rise to $17.1 Million - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

ANNOVIS BIO -REDH Earnings Results: $ANVS Reports Quarterly Earnings - Quiver Quantitative

Aug 12, 2025
pulisher
Aug 12, 2025

Annovis Reports Q2 2025 Financial Results, Drives Enrollment for Phase 3 AD Trial - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Annovis Bio, Inc. SEC 10-Q Report - TradingView

Aug 12, 2025
pulisher
Aug 12, 2025

Annovis Advances Alzheimer's Phase 3 Trial With 76 Sites, Reports Stronger Cash Position - Stock Titan

Aug 12, 2025
pulisher
Aug 11, 2025

Annovis Bio Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Aug 11, 2025
pulisher
Aug 10, 2025

Annovis Bio ANVS Q2 2025 Earnings Preview Upside Potential on Strategic Innovations - AInvest

Aug 10, 2025
pulisher
Aug 09, 2025

How sensitive is Annovis Bio Inc. to inflationTechnical Confluence Stock Ideas - mustnews.co.kr

Aug 09, 2025
pulisher
Aug 08, 2025

RSI Reset May Fuel Rebound in Annovis Bio Inc.Weekly Stock Watch With Growth Focus Expanded - beatles.ru

Aug 08, 2025
pulisher
Aug 07, 2025

Annovis Bio completes full patent transfer to crystal buntanetap - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Annovis Completes Full Patent Transfer to Crystal Buntanetap - Santé log

Aug 07, 2025
pulisher
Aug 07, 2025

Annovis secures IP protection for both forms of buntanetap By Investing.com - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

Annovis secures IP protection for both forms of buntanetap - Investing.com India

Aug 07, 2025
pulisher
Aug 07, 2025

Annovis Locks Down Patent Protection Until 2046 for Promising Alzheimer's and Parkinson's Treatment - Stock Titan

Aug 07, 2025
pulisher
Aug 04, 2025

Bullish Candlestick Pattern Forms in Annovis Bio Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it

Aug 04, 2025
pulisher
Aug 03, 2025

How many analysts rate Annovis Bio Inc. as a “Buy”Achieve rapid financial growth with expert picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Annovis Bio Inc. in the next 12 monthsAccelerated earnings growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Annovis Bio Inc. company’s key revenue driversFree Trend-Following Techniques - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Annovis Bio Inc. compare to its industry peersMassive portfolio appreciation - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Annovis Bio Inc. stock overvalued or undervaluedRapid growth trajectories - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

How volatile is Annovis Bio Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

Recovery Setup Building in Annovis Bio Inc. Experts SayStrong Buy With Technical Confidence Supported - metal.it

Aug 01, 2025
pulisher
Jul 31, 2025

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - 富途牛牛

Jul 31, 2025
pulisher
Jul 31, 2025

What catalysts could drive Annovis Bio Inc. stock higher in 2025Swing Trade Insights With Proven Results - Jammu Links News

Jul 31, 2025
pulisher
Jul 30, 2025

Will Annovis Bio Inc. Stock Benefit from AI and Green Energy TrendsTrade Scanner With Buy Zone Alerts Flagged - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Annovis Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Will Annovis Bio Inc. stock split in the near futureChart-Based Trade Entries Gain Analyst Support - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Annovis Bio Inc. stock in 2025Accelerated capital growth - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

Is Annovis Bio Inc. a growth stock or a value stockConsistently exceptional gains - Jammu Links News

Jul 28, 2025
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Capitalizzazione:     |  Volume (24 ore):